In addition, 7 ARGs (PLAU, EDA2R, AFP, PLG, TUBB3, APOBEC3G, and MALAT1) from ccRCC patient samples were combined to create a new ARGs signature that may be trusted to predict prognosis in ccRCC patients. Here, APOBEC3G is linked to nonpapillary renal cell carcinoma.